Branched-Tail Lipid Nanoparticles for Intravenous MRNA Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice

Overview

Journal Adv Healthc Mater

Specialties Biomedical Engineering
Biotechnology

Date 2024 Jun 18

PMID 38888972

Authors

Daria M Strelkova Petersen

Ryan M Weiss

Khalid A Hajj

Saigopalakrishna S Yerneni

Namit Chaudhary

Alexandra N Newby

Mariah L Arral

Kathryn A Whitehead

Affiliations

Soon will be listed here.

Abstract

Lipid nanoparticles (LNPs) are proven safe and effective delivery systems on a global scale. However, their efficacy has been limited primarily to liver and immune cell targets. To extend the applicability of mRNA drugs, 580 ionizable lipidoids are synthesized and tested for delivery to extrahepatocellular targets. Of these, over 40 enabled protein expression in mice, with the majority transfecting the liver. Beyond the liver, several LNPs containing new, branched-tail ionizable lipidoids potently delivered mRNA to the lungs, with cell-level specificity depending on helper lipid chemistry. Incorporation of the neutral helper lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) at 16 mol% enabled highly specific delivery to natural killer and dendritic cells within the lung. Although inclusion of the cationic lipid 1,2-di-(9Z-octadecenoyl)-3-trimethylammonium-propane (DOTAP) improved lung tropism, it decreased cell specificity, resulting in equal transfection of endothelial and lymphoid cells. DOTAP formulations are also less favorable than DOPE formulations because they elevated liver enzyme and cytokine levels. Together, these data identify a new branched-tailed LNP with a unique ability to selectively transfect lung immune cell populations without the use of toxicity-prone cationic helper lipids. This novel vehicle may unlock RNA therapies for lung diseases associated with immune cell dysregulation, including cancer, viral infections, and autoimmune disorders.

Citing Articles

Enhanced epigenetic modulation via mRNA-encapsulated lipid nanoparticles enables targeted anti-inflammatory control.

Mokhtari T, Taheri M, Akhlaghi S, Aryannejad A, Xiang Y, Mahajan V bioRxiv. 2025; .

PMID: 40060445 PMC: 11888353. DOI: 10.1101/2025.02.24.639996.

References

Billingsley M, Hamilton A, Mai D, Patel S, Swingle K, Sheppard N . Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. Nano Lett. 2021; 22(1):533-542. PMC: 9335860. DOI: 10.1021/acs.nanolett.1c02503. View

Ebrahimiyan H, Tamimi A, Shokoohian B, Minaei N, Memarnejadian A, Hossein-Khannazer N . Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int Immunopharmacol. 2022; 106:108587. DOI: 10.1016/j.intimp.2022.108587. View

Finn J, Rhoden Smith A, Patel M, Shaw L, Youniss M, van Heteren J . A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Rep. 2018; 22(9):2227-2235. DOI: 10.1016/j.celrep.2018.02.014. View

Akdis C, Akdis M, Boyd S, Sampath V, Galli S, Nadeau K . Allergy: Mechanistic insights into new methods of prevention and therapy. Sci Transl Med. 2023; 15(679):eadd2563. DOI: 10.1126/scitranslmed.add2563. View

Mohsenzadegan M, Peng R, Roudi R . Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape. J Cell Physiol. 2019; 235(1):74-86. DOI: 10.1002/jcp.28977. View

Guimaraes P, Zhang R, Spektor R, Tan M, Chung A, Billingsley M . Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening. J Control Release. 2019; 316:404-417. PMC: 7032071. DOI: 10.1016/j.jconrel.2019.10.028. View

Loughrey D, Dahlman J . Non-liver mRNA Delivery. Acc Chem Res. 2021; 55(1):13-23. DOI: 10.1021/acs.accounts.1c00601. View

Cai R, Chen C . The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine. Adv Mater. 2018; 31(45):e1805740. DOI: 10.1002/adma.201805740. View

Wang X, Liu S, Sun Y, Yu X, Lee S, Cheng Q . Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2022; 18(1):265-291. PMC: 9888002. DOI: 10.1038/s41596-022-00755-x. View

10.

Ryals R, Patel S, Acosta C, McKinney M, Pennesi M, Sahay G . The effects of PEGylation on LNP based mRNA delivery to the eye. PLoS One. 2020; 15(10):e0241006. PMC: 7595320. DOI: 10.1371/journal.pone.0241006. View

11.

Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M . Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020; 20(3):1578-1589. PMC: 7313236. DOI: 10.1021/acs.nanolett.9b04246. View

12.

Lokugamage M, Vanover D, Beyersdorf J, Hatit M, Rotolo L, Echeverri E . Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng. 2021; 5(9):1059-1068. PMC: 10197923. DOI: 10.1038/s41551-021-00786-x. View

13.

Gindy M, DiFelice K, Kumar V, Prudhomme R, Celano R, Haas R . Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery. Langmuir. 2014; 30(16):4613-22. DOI: 10.1021/la500630h. View

14.

Tam A, Kulkarni J, An K, Li L, Dorscheid D, Singhera G . Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. Eur J Pharm Sci. 2022; 176:106234. DOI: 10.1016/j.ejps.2022.106234. View

15.

Hajj K, Ball R, Deluty S, Singh S, Strelkova D, Knapp C . Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH. Small. 2019; 15(6):e1805097. DOI: 10.1002/smll.201805097. View

16.

Patel P, Ibrahim N, Cheng K . The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA. Trends Pharmacol Sci. 2021; 42(6):448-460. PMC: 8148296. DOI: 10.1016/j.tips.2021.03.002. View

17.

Zhang X, Zhao W, Nguyen G, Zhang C, Zeng C, Yan J . Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci Adv. 2020; 6(34). PMC: 7442477. DOI: 10.1126/sciadv.abc2315. View

18.

Kon E, Elia U, Peer D . Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol. 2021; 73:329-336. PMC: 8547895. DOI: 10.1016/j.copbio.2021.09.016. View

19.

Hung L, Ngo H, Van Pham P . Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment. Adv Exp Med Biol. 2020; 1292:113-130. DOI: 10.1007/5584_2020_522. View

20.

Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C . Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872770. DOI: 10.1073/pnas.2116271119. View